New drug TAX2 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called TAX2 for people with advanced solid tumors (ovarian, colorectal, pancreatic, or melanoma) that have not responded to standard treatments. The goal is to see if the drug is safe and if it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have ovarian, colorectal, pancreatic cancer, or melanoma that has come back or spread and standard treatments have stopped working.
- You are willing to have a tumor biopsy (a small sample taken) before and during treatment.
- You are able to do everyday activities (performance status 0 or 1).
- You do not have certain heart, lung, or autoimmune conditions, and your blood counts and organ function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
Hear when a new Solid Tumor Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.